Stockrabit · Analysts
Questions across 2 calls

Yash Tanna

ithought PMS

Alkem Laboratories Limited

Alkem Laboratories Limited CC-Mar24.pdf · 2024-05-29
Sir. I was just wondering about the medical devices business. I mean there were a couple of news articles relating to Alkem launching a couple of medical devices and I think you also mentioned probably in one of the media interviews. So, is this line of business we would probably look to make an acquisition, is that a possibility or if you can just elaborate about this line of business?
The medical devices there have been a couple of media articles relating to Alkem launching a couple of medical devices.
Alkem Laboratories Limited CC-Dec23.pdf · 2024-02-09
So this question is related to the previous participant. She mentioned about anti -infectives and pain. But even if I see respiratory and cardiac, right, there is some sort of underperf ormance even if I look at this quarter or 9 -month basis, so if you can provide a clarification there, what are we trying to do to bridge this gap? And secondly, my question was regarding the biosimilars. If you can provide an update on the pipeline and what are our plans going forward, probably in the medium term, next 2 to 3 years, how are we looking at launching these in the rest of the world markets and eventually into the regulated markets?
Just a follow-up. So we were looking to breakeven in Enzene, right, in the next year. So are we on track for that? And any timelines you would like to give for biosimilar launches probably in rest of the world or other markets?